Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, Inc., a biopharmaceutical company based in California, filed a Registration Statement with the U.S. Securities and Exchange Commission (SEC) on February 27, 2024. The filing, under Form S-8, is for the registration of an additional 4,839,367 shares of common stock. These shares are to be issued under the company's 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan, which have been previously effective through earlier registration statements. The additional shares are a result of automatic annual increase provisions in the plans. The company, incorporated in Delaware and led by President and CEO Todd Franklin Watanabe, is classified as a non-accelerated filer and a smaller reporting company. The filing includes references to earlier filed documents and exhibits, such as the Restated Certificate of Incorporation, Restated Bylaws, and forms of Common Stock Certificate, as well as legal opinions and consents from Latham & Watkins LLP and the company's independent registered public accounting firm.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company based in California, filed a Registration Statement with the U.S. Securities and Exchange Commission (SEC) on February 27, 2024. The filing, under Form S-8, is for the registration of an additional 4,839,367 shares of common stock. These shares are to be issued under the company's 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan, which have been previously effective through earlier registration statements. The additional shares are a result of automatic annual increase provisions in the plans. The company, incorporated in Delaware and led by President and CEO Todd Franklin Watanabe, is classified as a non-accelerated filer and a smaller reporting company. The filing includes references to earlier filed documents and exhibits, such as the Restated Certificate of Incorporation, Restated Bylaws, and forms of Common Stock Certificate, as well as legal opinions and consents from Latham & Watkins LLP and the company's independent registered public accounting firm.
总部位于加利福尼亚的生物制药公司Arcutis Biotherapeutics, Inc. 于2024年2月27日向美国证券交易委员会（SEC）提交了注册声明。根据S-8表格，该文件要求另外注册4,839,367股普通股。这些股票将根据公司的2020年股权激励计划和2020年员工股票购买计划发行，这两份计划此前已通过较早的注册声明生效。增加的股份是计划中每年自动增长条款的结果。该公司在特拉华州注册成立，由总裁兼首席执行官渡边托德·富兰克林领导，被列为非加速申报人和规模较小的申报公司。该文件包括对先前提交的文件和证物的引用，例如重述的公司注册证书、重述的章程和普通股证书的形式，以及瑞生和沃特金斯律师事务所和公司独立注册会计师事务所的法律意见和许可。
总部位于加利福尼亚的生物制药公司Arcutis Biotherapeutics, Inc. 于2024年2月27日向美国证券交易委员会（SEC）提交了注册声明。根据S-8表格，该文件要求另外注册4,839,367股普通股。这些股票将根据公司的2020年股权激励计划和2020年员工股票购买计划发行，这两份计划此前已通过较早的注册声明生效。增加的股份是计划中每年自动增长条款的结果。该公司在特拉华州注册成立，由总裁兼首席执行官渡边托德·富兰克林领导，被列为非加速申报人和规模较小的申报公司。该文件包括对先前提交的文件和证物的引用，例如重述的公司注册证书、重述的章程和普通股证书的形式，以及瑞生和沃特金斯律师事务所和公司独立注册会计师事务所的法律意见和许可。
有用
没用